Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
Status:
Terminated
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
The primary hypothesis of the study is that treatment with either once-daily or twice-daily
pacritinib results in a greater proportion of patients with thrombocytopenia and
myelofibrosis achieving ≥ 35% reduction in spleen volume from baseline to Week 24 than
treatment with Best Available Therapy, and a greater proportion of patients achieving a ≥ 50%
reduction in total symptom score from baseline to Week 24 as measured by the
Myeloproliferative Neoplasm Symptom Assessment Form 2.0.